BioMarin Pharmaceutical Inc. (BMRN)
BMRN Stock Price Chart
Explore BioMarin Pharmaceutical Inc. interactive price chart. Choose custom timeframes to analyze BMRN price movements and trends.
BMRN Company Profile
Discover essential business fundamentals and corporate details for BioMarin Pharmaceutical Inc. (BMRN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jul 1999
Employees
3.04K
Website
https://www.biomarin.comCEO
Alexander Hardy
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Financial Timeline
Browse a chronological timeline of BioMarin Pharmaceutical Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.89.
Earnings released on 4 Aug 2025
EPS came in at $1.44 surpassing the estimated $1.03 by +39.81%, while revenue for the quarter reached $825.41M , beating expectations by +2.33%.
Earnings released on 1 May 2025
EPS came in at $1.13 surpassing the estimated $0.94 by +20.21%, while revenue for the quarter reached $745.15M , missing expectations by -2.27%.
Earnings released on 19 Feb 2025
EPS came in at $0.92 surpassing the estimated $0.54 by +70.37%, while revenue for the quarter reached $738.22M , beating expectations by +3.64%.
Earnings released on 29 Oct 2024
EPS came in at $0.91 surpassing the estimated $0.78 by +16.67%, while revenue for the quarter reached $745.74M , beating expectations by +4.69%.
Earnings released on 5 Aug 2024
EPS came in at $0.96 surpassing the estimated $0.36 by +168.31%, while revenue for the quarter reached $708.66M , beating expectations by +6.73%.
Earnings released on 24 Apr 2024
EPS came in at $0.71 surpassing the estimated $0.31 by +127.71%, while revenue for the quarter reached $648.83M , missing expectations by -0.46%.
Earnings released on 22 Feb 2024
EPS came in at $0.49 surpassing the estimated $0.44 by +11.36%, while revenue for the quarter reached $646.21M , beating expectations by +1.50%.
Earnings released on 1 Nov 2023
EPS came in at $0.46 matching the estimated $0.46, while revenue for the quarter reached $585.97M , missing expectations by -7.90%.
Earnings released on 31 Jul 2023
EPS came in at $0.54 surpassing the estimated $0.47 by +14.89%, while revenue for the quarter reached $594.60M , missing expectations by -0.11%.
Earnings released on 26 Apr 2023
EPS came in at $0.60 surpassing the estimated $0.43 by +39.53%, while revenue for the quarter reached $592.95M , missing expectations by -0.99%.
Earnings released on 27 Feb 2023
EPS came in at $0.36 surpassing the estimated -$0.07 by +614.29%, while revenue for the quarter reached $537.54M , missing expectations by -0.02%.
Earnings released on 26 Oct 2022
EPS came in at $0.45 surpassing the estimated $0.37 by +21.62%, while revenue for the quarter reached $505.34M , missing expectations by -2.53%.
Earnings released on 3 Aug 2022
EPS came in at $0.59 surpassing the estimated $0.43 by +37.21%, while revenue for the quarter reached $533.80M , beating expectations by +2.61%.
Earnings released on 27 Apr 2022
EPS came in at $0.55 surpassing the estimated $0.38 by +44.74%, while revenue for the quarter reached $519.36M , beating expectations by +1.64%.
Earnings released on 23 Feb 2022
EPS came in at $0.03 surpassing the estimated $0.03 by +0.40%, while revenue for the quarter reached $449.81M , beating expectations by +1.68%.
Earnings released on 27 Oct 2021
EPS came in at $0.18 surpassing the estimated $0.11 by +63.64%, while revenue for the quarter reached $408.74M , missing expectations by -6.37%.
Earnings released on 28 Jul 2021
EPS came in at $0.53 surpassing the estimated $0.30 by +76.67%, while revenue for the quarter reached $501.69M , beating expectations by +14.79%.
Earnings released on 29 Apr 2021
EPS came in at $0.56 surpassing the estimated $0.32 by +75.00%, while revenue for the quarter reached $486.03M , beating expectations by +8.58%.
Earnings released on 25 Feb 2021
EPS came in at $0.21 surpassing the estimated $0.17 by +23.53%, while revenue for the quarter reached $452.12M , missing expectations by -57.78%.
Earnings released on 5 Nov 2020
EPS came in at $0.54 surpassing the estimated $0.25 by +116.00%, while revenue for the quarter reached $476.78M , beating expectations by +223.39%.
BMRN Stock Performance
Access detailed BMRN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.